MDM reports advisory board fees from Eisai, AstraZeneca, Janssen Pharmaceuticals, and Astellas Pharma, consultancy fees from Novartis, Roche, Pfizer, Takeda, and Merck Sharp & Dohme, and an institutional research grant from Tesaro–GlaxoSmithKline, unrelated to this Correspondence. MT declares travel, accommodations, and expenses supported by Roche, Bristol-Myers Squibb, AstraZeneca, and Takeda, and activity as a medical writer supported by Novartis and Amgen, unrelated to this Correspondence.